6 recruiting, 5 completed, 3 not yet recruiting, 1 terminated. 6 Phase 1, 6 Phase 2, 5 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 6 | Completed 2, Not yet recruiting 2, Recruiting 2 |
| Not applicable | 5 | Recruiting 3, Completed 1, Terminated 1 |
Follow Hearing Loss, Hidden: new trials by email Literature Review of Hearing Loss, Hidden trials Research Report on Hearing Loss, Hidden
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations CIL001 (Paliroden), Placebo - Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 135 | 2027-01-01 | 2026-10-26 |
| A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus paliroden (CIL001), Placebo - Tinnitus, Bilateral, Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 60 | 2027-01-01 | 2026-09-17 |
| Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder Whole exome sequencing. - Auditory Neuropathy Spectrum Disorder, Auditory Neuropathy | Not yet recruiting | Sohag University | 30 | 2026-08-01 | 2026-08-21 | |
| Hidden Hearing Loss in Older Adults Hidden Hearing Loss | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 200 | 2026-06-15 | 2026-06-12 | |
| Evaluation of the CochSyn Device in Clinical Practice CochSyn device - Hearing Loss, Sensorineural, Cochlear Hearing Loss | Not applicable | Completed | University Ghent | 65 | 2025-10-29 | 2026-02-10 |
| Relationship Between LS Chirp ABR and Speech-in-Noise Skills in Hidden Hearing Loss Hidden Hearing Loss, Cochlear Synaptopathy | Completed | Istanbul University - Cerrahpasa | 66 | 2025-08-20 | 2026-10-06 | |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss Cold pack-delivered mild therapeutic hypothermia - Noise Exposure, Noise-induced Hearing Loss | Not applicable | Recruiting | Restorear Devices LLC | 116 | 2024-12-19 | 2026-07-23 |
| Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans Phonak Lumina P90 - Auditory Diseases, Central | Not applicable | Recruiting | VA Office of Research and Development | 80 | 2024-04-01 | 2026-04-14 |
| A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients NS101, Placebo - Seneorineural Deafness, Sudden Sensorineural Hearing Loss | Phase 1 / Phase 2 | Recruiting | Neuracle Science Co., LTD. | 138 | 2024-01-19 | 2025-08-13 |
| Evaluation of the CochSyn Test Prototype to Measure Cochlear Synaptopathy CochSyn test prototype, Universal Smart Box (USB) - Hearing Loss, Sensorineural, Cochlear Synaptopathy | Not applicable | Terminated | University Ghent | 179 | 2023-11-13 | 2026-02-10 |
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss PIPE-505, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Contineum Therapeutics | 28 | 2020-10-15 | 2025-04-01 |
| Validation and Evaluation of the French Version of a Hearing Loss Screening Questionnaire in Adults Aged 60 Years Old and More HHIE-S survey score - Hearing Loss | Completed | University Hospital, Bordeaux | 294 | 2019-11-07 | 2020-06-05 | |
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment OTO-413, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 110 | 2019-10-01 | 2022-10-27 |
| Optimization of a Non-invasive Electrophysiological Method for Studying the Functionality of Auditory Nerve Fibers Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways - Healthy Volunteer, Without Hearing Disorders | Not applicable | Recruiting | University Hospital, Clermont-Ferrand | 220 | 2019-04-29 | 2026-06-17 |
Hearing Loss (6) · Hearing Loss, Sensorineural (6) · Auditory Diseases, Central (2) · Hearing Disorders (2) · Hearing Loss, Noise-Induced (2) · Presbycusis (2) · Auditory Perceptual Disorders (1) · Auditory neuropathy (1) · Blast Injuries (1) · Deafness (1) · Deafness, Autosomal Recessive 9 (1) · Diabetes Mellitus (1) · Hearing Loss, Central (1) · Hearing Loss, Sudden (1)
Ear Diseases (15) · Nervous System Diseases (15) · Neurologic Manifestations (15) · Otorhinolaryngologic Diseases (15) · Pathological Conditions, Signs and Symptoms (15) · Sensation Disorders (15) · Signs and Symptoms (15) · Hearing Disorders (13) · Hearing Loss (9) · Hearing Loss, Sensorineural (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Retrocochlear Diseases (2) · Barotrauma (1)
Audiometry, Evoked Response (1) · Clemastine (1) · Exome (1) · Placebo Effect (1)
Cilcare SAS (2) · University Ghent (2) · Contineum Therapeutics (1) · Istanbul University - Cerrahpasa (1) · Neuracle Science Co., LTD. (1) · Otonomy, Inc. (1) · Restorear Devices LLC (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Sohag University (1) · University Hospital, Bordeaux (1) · University Hospital, Clermont-Ferrand (1) · University of Colorado, Denver (1) · VA Office of Research and Development (1)
United States (5) · Belgium (2) · France (2) · China (1) · Egypt (1) · South Korea (1) · Turkey (Türkiye) (1)
Sarah Verhulst, Prof. (2) · Achim Klug, PhD (1) · Eyyup Kara, Asst. Prof. (1) · Fabrice Giraudet (1) · Jonathan Venezia, PhD (1) · Joseph Park, M.D. (1) · Samuel A Budoff, PhD, MS (1) · Stephen Huhn, MD (1) · Suhrud M Rajguru, PhD (1)
PMID 12809326, PMID 19409623, PMID 19906956, PMID 22939890, PMID 25400543, PMID 26691159, PMID 26818607, PMID 26833137, PMID 27340636, PMID 27729456, PMID 28696301, PMID 29111973, PMID 29688962, PMID 30482216, PMID 31453354, PMID 32209515, PMID 33908410, PMID 34424407, PMID 34942983, PMID 36769387, PMID 37679651, PMID 38335624, PMID 41085057, PMID 42279121, PMID 42479273
2025 (1), I01RX005059 (1), R44DC018760 (1)